Close

Biocon Q4 net profit falls 54% to Rs 113 crore

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Predictive AI in Pharma Cold Chain Risk Management

Revolutionizing Cold Chain Management Through Artificial Intelligence The pharmaceutical industry...

Transforming Pharma Cold Chain Using IoT Real-Time Tracking

Transforming Pharmaceutical Cold Chain Through Connected Intelligence The pharmaceutical industry...

SOPs for Temperature-Sensitive Pharma Products Logistics

The Foundation of Temperature-Controlled Pharmaceutical Logistics The pharmaceutical industry operates...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

Biotechnology firm Biocon on Friday reported a 54.51 per cent fall in its consolidated net profit at Rs 113.08 crore for the fourth quarter ended March 31, 2014.
The company had posted a net profit of Rs 248.61 crore in the same period of the previous fiscal.

Net sales of the company rose to Rs 722.59 crore for the fourth quarter as against Rs 630.12 crore for the same period a year ago, Biocon Ltd said in a statement.
For the year ended March 31, 2014, the company’s net profit declined by 18.69 per cent to Rs 413.72 crore from Rs 508.82 crore in the 2012-13 fiscal.
The company’s net sales for the just-concluded fiscal rose to Rs 2,852.72 crore, as against Rs 2,427.60 crore in the previous year.
In a separate statement, the Bangalore-based firm said it has appointed Arun Chandavarkar as the Chief Executive Officer and Joint Managing Director.
The company’s board also recommended a final dividend of Rs 5 per share (100 per cent) for the FY 2013-14.
Biocon shares were trading at Rs 481.10 apiece on the BSE, up 3.04 per cent from its previous close.

 

Latest stories

Related stories

Predictive AI in Pharma Cold Chain Risk Management

Revolutionizing Cold Chain Management Through Artificial Intelligence The pharmaceutical industry...

Transforming Pharma Cold Chain Using IoT Real-Time Tracking

Transforming Pharmaceutical Cold Chain Through Connected Intelligence The pharmaceutical industry...

SOPs for Temperature-Sensitive Pharma Products Logistics

The Foundation of Temperature-Controlled Pharmaceutical Logistics The pharmaceutical industry operates...

Evolution of Multi-Omic Integration in Precision Medicine

The convergence of genomics, proteomics, transcriptomics, metabolomics, and pathology...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back